Immunotherapy Archives

valo therapeutics oxford finland cancer immunotherapy

Startup Scout 27 Mar 2020

This Startup is Making a Cancer Vaccine out of Viruses

Valo Therapeutics is operating both in the UK and Finland to develop a cancer vaccine based on a virus designed to kill tumors. Mission: To combine two different immunotherapy techniques — oncolytic viruses and cancer vaccines — into one treatment for solid tumors. Immunotherapy has transformed the cancer treatment landscape, offering therapies such as checkpoint […]

March 27, 2020 - 4 minutesmins - By Jonathan Smith

Startup Scout 13 Mar 2020

This Startup Hits Hidden Proteins to Make Cancer Immunotherapies

With one foot in Belgium and another in the US, Orionis Biosciences combines US and European talent to develop cancer immunotherapies targeting difficult protein targets. Mission: To fight cancer with two technologies. The first is modifying immune proteins called cytokines to trigger the body to produce specific immune cells against a tumor. The second is […]

March 13, 2020 - 4 minutesmins - By Jonathan Smith

News and Trends 26 Feb 2020

Bicycle Therapeutics Partners Genentech in Deal Worth €1.6B

UK biotech Bicycle Therapeutics will collaborate with Genentech, now part of the Roche Group, to develop novel cancer immunotherapies and take them to market. Genentech will pay €28M upfront to Bicycle, but if discovery, regulatory and commercial milestones are met then the deal could be worth up to €1.6B for the Cambridge-based company. Bicycle’s technology […]

February 26, 2020 - 2 minutesmins - By Helen Albert

Best in Biotech 24 Feb 2020

Meet 20 European Immuno-Oncology Companies that are Fighting Cancer

With the success of CAR T-cell therapies and other innovative medicines in this area, immuno-oncology has become a buzzword in biotech, with more and more companies starting up in Europe and elsewhere. With so many players involved, it can be hard to know who is doing what. Here are 20 European companies we think stand […]

February 24, 2020 - 12 minutesmins - By Larissa Warneck-Silvestrin

Interview 5 Feb 2020

Harnessing Genetic Suppression to Treat Rare Disease

Through quirks of genetics, some people are naturally resilient to heritable diseases. Thijn Brummelkamp, Managing Director and founder of the Dutch startup Scenic Biotech, explains how the company is using this genetic resilience to treat rare diseases and cancer. Heritable diseases result from genetic mutations that cause essential proteins in the body to malfunction. For […]

February 5, 2020 - 5 minutesmins - By Jonathan Smith

Startup Scout 31 Jan 2020

This Cancer Immunotherapy Attacks the Sugar Coat of Tumor Cells

The Portuguese company CellmAbs is developing cancer immunotherapies that prevent tumor cells from evading the immune system by hitting sugar molecules on their surface. Mission: To develop drugs that bind with a type of sugar molecules only found on the surface of cancer cells called aberrant glycans. Some of these aberrant glycans are able to […]

January 31, 2020 - 3 minutesmins - By Jonathan Smith

cancer vaccine cancer immunotherapy ervaxx

News and Trends 27 Jan 2020

UK Startup Snaps up Potential Universal Cancer Immunotherapy

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments […]

January 27, 2020 - 2 minutesmins - By Jonathan Smith

pdcLine Pharma dendritic cell cancer vaccine

News and Trends 22 Jan 2020

Off-The-Shelf Lung Cancer Vaccine Clinical Trial Gets €20M Boost

The French-Belgian company PDC*Line Pharma has raised a €20M Series B round to fund an ongoing phase I/II trial of its off-the-shelf therapeutic vaccine for lung cancer. The total €20M consists of €13.9M in equity investments and €6.1M in loans and subsidies from the Walloon Region of Belgium. PDC*Line’s current investors took part in the […]

January 22, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 16 Jan 2020

BioNTech Expands Cancer Portfolio With US Biotech Acquisition

German cancer specialist BioNTech will acquire US T-cell therapy biotech Neon Therapeutics in a deal worth €60M, both to expand its cancer therapy pipeline and establish a US base. The deal is expected to complete in the second half of 2020, after which Neon will operate as a subsidiary of BioNTech. BioNTech has arguably scooped […]

January 16, 2020 - 2 minutesmins - By Helen Albert

tumor cancer immunotherapy alderaan biotech

News and Trends 9 Jan 2020

French Biotech Raises €19M to Hit Phase I with Cancer Immunotherapy

Alderaan Biotechnology has raised an €18.5M Series A round to push its lead cancer immunotherapy drug to phase I. The UK VC firm Medicxi and the returning French VC investor Advent France Biotechnology contributed to the round. Alderaan, whose name was inspired by a fictional planet in the Star Wars movies, will use part of […]

January 9, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 13 Dec 2019

Transgene’s Cancer Vaccine Abandoned after Phase II Fail

French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial. In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to […]

December 13, 2019 - 2 minutesmins - By Jonathan Smith

cancer immunotherapy immunos therapeutics

News and Trends 11 Dec 2019

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […]

December 11, 2019 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us